Physician profile
Robert Coffin
NPI 1942565502
$1,351.56
in general payments reported to CMS, 2019-2025
20 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.64 · 2021: $113 · 2022: $230 · 2023: $724 · 2024: $34.90 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $942.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $235.96 | 2021-2023 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $226.18 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $160.68 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $133.12 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Pfizer INC. | $124.65 | 2019-2023 | |
| Glaxosmithkline, LLC. | $76.97 | 2022-2025 | Shingrix, Bexsero, Trelegy Ellipta |
| Amgen INC. | $55.57 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.31 | 2022-2023 | Jardiance |
| Neurocrine Biosciences, INC. | $37.27 | 2025 | |
| Exact Sciences Corporation | $36.49 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $29.67 | 2023 | Quviviq |
| Abbott Laboratories | $29.45 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $25.09 | 2022 | |
| Viiv Healthcare Company | $23.24 | 2025 | Dovato |
| Sumitomo Pharma America, INC. | $22.42 | 2023 | Gemtesa |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $21.44 | 2023 | |
| Novartis Pharmaceuticals Corporation | $19.33 | 2023 | |
| Insulet Corporation | $19.32 | 2024 | Omnipod |
| Lucid Diagnostics INC. | $16.35 | 2023 | |
| Eisai INC. | $13.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Coffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.